Thermo Fisher And SHL Medical Partner To Build Integrated Autoinjector And Sterile Manufacturing Hub In The U.S.

Thermo Fisher Scientific Inc. has announced a strategic collaboration with SHL Medical, alongside expanding its sterile fill-finish and autoinjector assembly capabilities at its Ridgefield, New Jersey facility. This move aims to create a fully integrated, U.S.-based solution covering sterile manufacturing, device assembly, and commercial packaging for drug-device combination products.

The initiative responds to growing demand for patient-friendly, self-administered injectable therapies across areas such as autoimmune and chronic diseases. To address this, Thermo Fisher is increasing its pre-filled syringe (PFS) fill-finish capacity and device assembly operations at the Ridgefield site. The partnership will also integrate SHL Medical’s Molly® autoinjector platform with Thermo Fisher’s sterile manufacturing network, enabling a streamlined, end-to-end production process.

“The collaboration with SHL Medical, a global leader in autoinjectors, and our expansion in Ridgefield are important steps in helping our customers meet growing demand,” said Michelle Logan, Vice President, Drug Product – Steriles, North America, Thermo Fisher. “By fully integrating fill-finish with device assembly, we can simplify supply chains, accelerate timelines and ultimately support our customers in delivering critical therapies to patients more efficiently.”

Thermo Fisher acquired the Ridgefield facility from Sanofi in September 2025 as part of its broader strategy to strengthen its U.S. manufacturing footprint. The site is being positioned as a key North American hub for sterile fill-finish, autoinjector assembly, and packaging, enhancing domestic supply chain capabilities for pharmaceutical clients.

“This collaboration with Thermo Fisher represents a significant milestone for SHL Medical and for the customers we jointly serve,” said Markus Puusepp, Chief Growth Officer, SHL Medical. “By combining SHL Medical’s proven Molly® autoinjector platform and global device expertise with Thermo Fisher’s leading sterile fill-finish and commercial manufacturing capabilities, we are creating a powerful, integrated solution. This installation in Ridgefield underscores our shared commitment to supporting the growing demand for high-quality, patient-centric combination products and accelerating time to market for innovative therapies worldwide.”

Under the non-exclusive collaboration, both companies will support the Molly® autoinjector platform through final device assembly, packaging, and distribution at Ridgefield. This expansion complements Thermo Fisher’s global sterile manufacturing network, including sites in Pennsylvania, the UK, and upcoming capacity in North Carolina, along with continued investments in Italy and the Asia-Pacific region.